Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Anti-viral effects of interferon-λ3 on hepatitis B virus infection in cell culture.

Yamada N, Murayama A, Shiina M, Aly HH, Iwamoto M, Tsukuda S, Watashi K, Tanaka T, Moriishi K, Nishitsuji H, Sugiyama M, Mizokami M, Shimotohno K, Muramatsu M, Murata K, Kato T.

Hepatol Res. 2019 Nov 22. doi: 10.1111/hepr.13449. [Epub ahead of print]

PMID:
31756766
2.

Potential Risk of Virus Carryover by Fabrics of Personal Protective Gowns.

Katoh I, Tanabe F, Kasai H, Moriishi K, Shimasaki N, Shinohara K, Uchida Y, Koshiba T, Arakawa S, Morimoto M.

Front Public Health. 2019 May 22;7:121. doi: 10.3389/fpubh.2019.00121. eCollection 2019.

3.

C-terminal α Domain of p63 Binds to p300 to Coactivate β-Catenin.

Katoh I, Maehata Y, Moriishi K, Hata RI, Kurata SI.

Neoplasia. 2019 May;21(5):494-503. doi: 10.1016/j.neo.2019.03.010. Epub 2019 Apr 12.

4.

HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers.

Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.

PLoS One. 2019 Feb 22;14(2):e0212559. doi: 10.1371/journal.pone.0212559. eCollection 2019.

5.

USP15 Participates in Hepatitis C Virus Propagation through Regulation of Viral RNA Translation and Lipid Droplet Formation.

Kusakabe S, Suzuki T, Sugiyama Y, Haga S, Horike K, Tokunaga M, Hirano J, Zhang H, Chen DV, Ishiga H, Komoda Y, Ono C, Fukuhara T, Yamamoto M, Ikawa M, Satoh T, Akira S, Tanaka T, Moriishi K, Fukai M, Taketomi A, Yoshio S, Kanto T, Suzuki T, Okamoto T, Matsuura Y.

J Virol. 2019 Mar 5;93(6). pii: e01708-18. doi: 10.1128/JVI.01708-18. Print 2019 Mar 15.

6.

Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma.

Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Shindo H, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.

Hepatol Res. 2019 Jan;49(1):51-63. doi: 10.1111/hepr.13277. Epub 2018 Dec 27.

PMID:
30350374
7.

Roles of the 5' Untranslated Region of Nonprimate Hepacivirus in Translation Initiation and Viral Replication.

Tanaka T, Otoguro T, Yamashita A, Kasai H, Fukuhara T, Matsuura Y, Moriishi K.

J Virol. 2018 Mar 14;92(7). pii: e01997-17. doi: 10.1128/JVI.01997-17. Print 2018 Apr 1.

8.

Seroepidemiology of non-primate hepacivirus (NPHV) in Japanese native horses.

Hayashi S, Tanaka T, Moriishi K, Hirayama K, Yamada A, Hotta K.

J Vet Med Sci. 2018 Feb 2;80(1):186-189. doi: 10.1292/jvms.17-0527. Epub 2017 Nov 29.

9.

Characterization of SPP inhibitors suppressing propagation of HCV and protozoa.

Hirano J, Okamoto T, Sugiyama Y, Suzuki T, Kusakabe S, Tokunaga M, Fukuhara T, Sasai M, Tougan T, Matsunaga Y, Yamashita K, Sakai Y, Yamamoto M, Horii T, Standley DM, Moriishi K, Moriya K, Koike K, Matsuura Y.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):E10782-E10791. doi: 10.1073/pnas.1712484114. Epub 2017 Nov 29.

10.

Insights into the mechanism of isoenzyme-specific signal peptide peptidase-mediated translocation of heme oxygenase.

Schaefer B, Moriishi K, Behrends S.

PLoS One. 2017 Nov 20;12(11):e0188344. doi: 10.1371/journal.pone.0188344. eCollection 2017.

11.

Inhibitory effects of metachromin A on hepatitis B virus production via impairment of the viral promoter activity.

Yamashita A, Tamaki M, Kasai H, Tanaka T, Otoguro T, Ryo A, Maekawa S, Enomoto N, de Voogd NJ, Tanaka J, Moriishi K.

Antiviral Res. 2017 Sep;145:136-145. doi: 10.1016/j.antiviral.2017.08.001. Epub 2017 Aug 4.

PMID:
28827084
12.

The potential of signal peptide peptidase as a therapeutic target for hepatitis C.

Moriishi K.

Expert Opin Ther Targets. 2017 Sep;21(9):827-836. doi: 10.1080/14728222.2017.1369959. Epub 2017 Aug 22. Review.

PMID:
28820612
13.

Cinnamic acid derivatives inhibit hepatitis C virus replication via the induction of oxidative stress.

Amano R, Yamashita A, Kasai H, Hori T, Miyasato S, Saito S, Yokoe H, Takahashi K, Tanaka T, Otoguro T, Maekawa S, Enomoto N, Tsubuki M, Moriishi K.

Antiviral Res. 2017 Sep;145:123-130. doi: 10.1016/j.antiviral.2017.07.018. Epub 2017 Aug 2.

PMID:
28780423
14.

Hepatitis B virus prevents excessive viral production via reduction of cell death-inducing DFF45-like effectors.

Yasumoto J, Kasai H, Yoshimura K, Otoguro T, Watashi K, Wakita T, Yamashita A, Tanaka T, Takeda S, Moriishi K.

J Gen Virol. 2017 Jul;98(7):1762-1773. doi: 10.1099/jgv.0.000813.

PMID:
28745269
15.

Immunological function of Langerhans cells in HIV infection.

Matsuzawa T, Ogawa Y, Moriishi K, Shimada S, Kawamura T.

J Dermatol Sci. 2017 Aug;87(2):159-167. doi: 10.1016/j.jdermsci.2017.03.015. Epub 2017 Apr 9.

PMID:
28433429
16.

Four Aromatic Sulfates with an Inhibitory Effect against HCV NS3 Helicase from the Crinoid Alloeocomatella polycladia.

Hermawan I, Furuta A, Higashi M, Fujita Y, Akimitsu N, Yamashita A, Moriishi K, Tsuneda S, Tani H, Nakakoshi M, Tsubuki M, Sekiguchi Y, Noda N, Tanaka J.

Mar Drugs. 2017 Apr 11;15(4). pii: E117. doi: 10.3390/md15040117.

17.
18.

Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation.

Tanaka T, Okuyama-Dobashi K, Murakami S, Chen W, Okamoto T, Ueda K, Hosoya T, Matsuura Y, Ryo A, Tanaka Y, Hagiwara M, Moriishi K.

Antiviral Res. 2016 Sep;133:156-64. doi: 10.1016/j.antiviral.2016.08.008. Epub 2016 Aug 8.

PMID:
27515132
19.

TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis.

Aizawa S, Okamoto T, Sugiyama Y, Kouwaki T, Ito A, Suzuki T, Ono C, Fukuhara T, Yamamoto M, Okochi M, Hiraga N, Imamura M, Chayama K, Suzuki R, Shoji I, Moriishi K, Moriya K, Koike K, Matsuura Y.

Nat Commun. 2016 May 4;7:11379. doi: 10.1038/ncomms11379.

20.

Repression of Wnt/β-catenin response elements by p63 (TP63).

Katoh I, Fukunishi N, Fujimuro M, Kasai H, Moriishi K, Hata R, Kurata S.

Cell Cycle. 2016;15(5):699-710. doi: 10.1080/15384101.2016.1148837.

21.

The Alarmin IL-33 Derived from HSV-2-Infected Keratinocytes Triggers Mast Cell-Mediated Antiviral Innate Immunity.

Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Moriishi K, Nakao A, Shimada S.

J Invest Dermatol. 2016 Jun;136(6):1290-1292. doi: 10.1016/j.jid.2016.01.030. Epub 2016 Feb 9. No abstract available.

22.

Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx.

Kouwaki T, Okamoto T, Ito A, Sugiyama Y, Yamashita K, Suzuki T, Kusakabe S, Hirano J, Fukuhara T, Yamashita A, Saito K, Okuzaki D, Watashi K, Sugiyama M, Yoshio S, Standley DM, Kanto T, Mizokami M, Moriishi K, Matsuura Y.

J Virol. 2016 Jan 20;90(7):3530-42. doi: 10.1128/JVI.02776-15.

23.

Hepatitis B virus efficiently infects non-adherent hepatoma cells via human sodium taurocholate cotransporting polypeptide.

Okuyama-Dobashi K, Kasai H, Tanaka T, Yamashita A, Yasumoto J, Chen W, Okamoto T, Maekawa S, Watashi K, Wakita T, Ryo A, Suzuki T, Matsuura Y, Enomoto N, Moriishi K.

Sci Rep. 2015 Nov 23;5:17047. doi: 10.1038/srep17047.

24.

Involvement of FKBP6 in hepatitis C virus replication.

Kasai H, Kawakami K, Yokoe H, Yoshimura K, Matsuda M, Yasumoto J, Maekawa S, Yamashita A, Tanaka T, Ikeda M, Kato N, Okamoto T, Matsuura Y, Sakamoto N, Enomoto N, Takeda S, Fujii H, Tsubuki M, Kusunoki M, Moriishi K.

Sci Rep. 2015 Nov 16;5:16699. doi: 10.1038/srep16699.

25.

Identification of Antiviral Agents Targeting Hepatitis B Virus Promoter from Extracts of Indonesian Marine Organisms by a Novel Cell-Based Screening Assay.

Yamashita A, Fujimoto Y, Tamaki M, Setiawan A, Tanaka T, Okuyama-Dobashi K, Kasai H, Watashi K, Wakita T, Toyama M, Baba M, de Voogd NJ, Maekawa S, Enomoto N, Tanaka J, Moriishi K.

Mar Drugs. 2015 Nov 6;13(11):6759-73. doi: 10.3390/md13116759.

26.

Identification of Hydroxyanthraquinones as Novel Inhibitors of Hepatitis C Virus NS3 Helicase.

Furuta A, Tsubuki M, Endoh M, Miyamoto T, Tanaka J, Salam KA, Akimitsu N, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Sekiguchi Y, Tsuneda S, Noda N.

Int J Mol Sci. 2015 Aug 7;16(8):18439-53. doi: 10.3390/ijms160818439.

27.

Novel sex-dependent differentially methylated regions are demethylated in adult male mouse livers.

Ito S, Hirabayashi K, Moriishi K, Matsui Y, Moriya K, Koike K, Matsuura Y, Shiota K, Yagi S.

Biochem Biophys Res Commun. 2015 Jul 10;462(4):332-8. doi: 10.1016/j.bbrc.2015.04.137. Epub 2015 May 8.

PMID:
25960295
28.

Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.

Sato M, Maekawa S, Komatsu N, Tatsumi A, Miura M, Muraoka M, Suzuki Y, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Uetake T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.

J Virol. 2015 Jun;89(11):6105-16. doi: 10.1128/JVI.03127-14. Epub 2015 Mar 25.

29.

Maternal restraint stress during pregnancy in mice induces 11β-HSD1-associated metabolic changes in the livers of the offspring.

Maeyama H, Hirasawa T, Tahara Y, Obata C, Kasai H, Moriishi K, Mochizuki K, Kubota T.

J Dev Orig Health Dis. 2015 Apr;6(2):105-14. doi: 10.1017/S2040174415000100. Epub 2015 Feb 24.

PMID:
25708481
30.

Long-term imipramine treatment increases N-methyl-d-aspartate receptor activity and expression via epigenetic mechanisms.

Nghia NA, Hirasawa T, Kasai H, Obata C, Moriishi K, Mochizuki K, Koizumi S, Kubota T.

Eur J Pharmacol. 2015 Apr 5;752:69-77. doi: 10.1016/j.ejphar.2015.02.010. Epub 2015 Feb 19.

PMID:
25701723
31.

Hallmarks of hepatitis C virus in equine hepacivirus.

Tanaka T, Kasai H, Yamashita A, Okuyama-Dobashi K, Yasumoto J, Maekawa S, Enomoto N, Okamoto T, Matsuura Y, Morimatsu M, Manabe N, Ochiai K, Yamashita K, Moriishi K.

J Virol. 2014 Nov;88(22):13352-66. doi: 10.1128/JVI.02280-14. Epub 2014 Sep 10.

32.

PBDE: structure-activity studies for the inhibition of hepatitis C virus NS3 helicase.

Salam KA, Furuta A, Noda N, Tsuneda S, Sekiguchi Y, Yamashita A, Moriishi K, Nakakoshi M, Tani H, Roy SR, Tanaka J, Tsubuki M, Akimitsu N.

Molecules. 2014 Apr 2;19(4):4006-20. doi: 10.3390/molecules19044006.

33.

Binding of HSV-1 glycoprotein K (gK) to signal peptide peptidase (SPP) is required for virus infectivity.

Allen SJ, Mott KR, Matsuura Y, Moriishi K, Kousoulas KG, Ghiasi H.

PLoS One. 2014 Jan 20;9(1):e85360. doi: 10.1371/journal.pone.0085360. eCollection 2014.

34.

Identification and biochemical characterization of halisulfate 3 and suvanine as novel inhibitors of hepatitis C virus NS3 helicase from a marine sponge.

Furuta A, Salam KA, Hermawan I, Akimitsu N, Tanaka J, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Tsubuki M, Peng PW, Suzuki Y, Yamamoto N, Sekiguchi Y, Tsuneda S, Noda N.

Mar Drugs. 2014 Jan 21;12(1):462-76. doi: 10.3390/md12010462.

35.

EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.

Matsuzawa T, Kawamura T, Ogawa Y, Maeda K, Nakata H, Moriishi K, Koyanagi Y, Gatanaga H, Shimada S, Mitsuya H.

J Invest Dermatol. 2014 Apr;134(4):1158-1161. doi: 10.1038/jid.2013.467. Epub 2013 Nov 11. No abstract available.

36.

Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus.

Shen H, Yamashita A, Nakakoshi M, Yokoe H, Sudo M, Kasai H, Tanaka T, Fujimoto Y, Ikeda M, Kato N, Sakamoto N, Shindo H, Maekawa S, Enomoto N, Tsubuki M, Moriishi K.

PLoS One. 2013 Dec 17;8(12):e82299. doi: 10.1371/journal.pone.0082299. eCollection 2013.

37.

Deep-sequencing analysis of the association between the quasispecies nature of the hepatitis C virus core region and disease progression.

Miura M, Maekawa S, Takano S, Komatsu N, Tatsumi A, Asakawa Y, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.

J Virol. 2013 Dec;87(23):12541-51. doi: 10.1128/JVI.00826-13. Epub 2013 Aug 14.

38.

Microglia release ATP by exocytosis.

Imura Y, Morizawa Y, Komatsu R, Shibata K, Shinozaki Y, Kasai H, Moriishi K, Moriyama Y, Koizumi S.

Glia. 2013 Aug;61(8):1320-30. doi: 10.1002/glia.22517. Epub 2013 Jul 5.

PMID:
23832620
39.

Effects of immunization of pregnant guinea pigs with guinea pig cytomegalovirus glycoprotein B on viral spread in the placenta.

Hashimoto K, Yamada S, Katano H, Fukuchi S, Sato Y, Kato M, Yamaguchi T, Moriishi K, Inoue N.

Vaccine. 2013 Jun 28;31(31):3199-205. doi: 10.1016/j.vaccine.2013.04.078. Epub 2013 May 15.

PMID:
23684839
40.

Understanding the biological context of NS5A-host interactions in HCV infection: a network-based approach.

Tripathi LP, Kambara H, Chen YA, Nishimura Y, Moriishi K, Okamoto T, Morita E, Abe T, Mori Y, Matsuura Y, Mizuguchi K.

J Proteome Res. 2013 Jun 7;12(6):2537-51. doi: 10.1021/pr3011217. Epub 2013 May 17.

PMID:
23682656
41.

Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium.

Matsuzawa T, Kawamura T, Ogawa Y, Takahashi M, Aoki R, Moriishi K, Koyanagi Y, Gatanaga H, Blauvelt A, Shimada S.

J Invest Dermatol. 2013 Dec;133(12):2803-2805. doi: 10.1038/jid.2013.215. Epub 2013 May 6. No abstract available.

42.

Mast cells play a key role in host defense against herpes simplex virus infection through TNF-α and IL-6 production.

Aoki R, Kawamura T, Goshima F, Ogawa Y, Nakae S, Nakao A, Moriishi K, Nishiyama Y, Shimada S.

J Invest Dermatol. 2013 Sep;133(9):2170-9. doi: 10.1038/jid.2013.150. Epub 2013 Mar 25.

43.

Ca(2+) /S100 proteins regulate HCV virus NS5A-FKBP8/FKBP38 interaction and HCV virus RNA replication.

Tani J, Shimamoto S, Mori K, Kato N, Moriishi K, Matsuura Y, Tokumitsu H, Tsuchiya M, Fujimoto T, Kato K, Miyoshi H, Masaki T, Kobayashi R.

Liver Int. 2013 Aug;33(7):1008-18. doi: 10.1111/liv.12151. Epub 2013 Mar 24.

PMID:
23522085
44.

IL-28B (IFN-λ3) and IFN-α synergistically inhibit HCV replication.

Shindo H, Maekawa S, Komase K, Miura M, Kadokura M, Sueki R, Komatsu N, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.

J Viral Hepat. 2013 Apr;20(4):281-9. doi: 10.1111/j.1365-2893.2012.01649.x. Epub 2012 Aug 7.

PMID:
23490373
45.

Cholesterol sulfate as a potential inhibitor of hepatitis C virus NS3 helicase.

Furuta A, Salam KA, Akimitsu N, Tanaka J, Tani H, Yamashita A, Moriishi K, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Noda N.

J Enzyme Inhib Med Chem. 2014 Apr;29(2):223-9. doi: 10.3109/14756366.2013.766607. Epub 2013 Feb 25.

PMID:
23432541
46.

Psammaplin A inhibits hepatitis C virus NS3 helicase.

Salam KA, Furuta A, Noda N, Tsuneda S, Sekiguchi Y, Yamashita A, Moriishi K, Nakakoshi M, Tsubuki M, Tani H, Tanaka J, Akimitsu N.

J Nat Med. 2013 Oct;67(4):765-72. doi: 10.1007/s11418-013-0742-7. Epub 2013 Jan 29.

PMID:
23359228
47.

Antimicrobial peptide LL-37 produced by HSV-2-infected keratinocytes enhances HIV infection of Langerhans cells.

Ogawa Y, Kawamura T, Matsuzawa T, Aoki R, Gee P, Yamashita A, Moriishi K, Yamasaki K, Koyanagi Y, Blauvelt A, Shimada S.

Cell Host Microbe. 2013 Jan 16;13(1):77-86. doi: 10.1016/j.chom.2012.12.002. Epub 2013 Jan 16.

48.

Serum RANTES level influences the response to pegylated interferon and ribavirin therapy in chronic hepatitis C.

Komase K, Maekawa S, Miura M, Sueki R, Kadokura M, Shindo H, Shindo K, Amemiya F, Nakayama Y, Inoue T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N.

Hepatol Res. 2013 Aug;43(8):865-75. doi: 10.1111/hepr.12032. Epub 2012 Dec 28.

PMID:
23279319
49.

Inhibition of both protease and helicase activities of hepatitis C virus NS3 by an ethyl acetate extract of marine sponge Amphimedon sp.

Fujimoto Y, Salam KA, Furuta A, Matsuda Y, Fujita O, Tani H, Ikeda M, Kato N, Sakamoto N, Maekawa S, Enomoto N, de Voogd NJ, Nakakoshi M, Tsubuki M, Sekiguchi Y, Tsuneda S, Akimitsu N, Noda N, Yamashita A, Tanaka J, Moriishi K.

PLoS One. 2012;7(11):e48685. doi: 10.1371/journal.pone.0048685. Epub 2012 Nov 7.

50.

Upregulation of nuclear PA28γ expression in cirrhosis and hepatocellular carcinoma.

Kondo M, Moriishi K, Wada H, Noda T, Marubashi S, Wakasa K, Matsuura Y, Doki Y, Mori M, Nagano H.

Exp Ther Med. 2012 Mar;3(3):379-385. Epub 2011 Dec 14.

Supplemental Content

Loading ...
Support Center